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Food insecurity is a growing issue in the United States. Iron deficiency is the most common 
form of nutritional deficiency in patients with endothelial dysfunction and vascular-related 
diseases. This preliminary study lays the groundwork for the “Nutrient deficiency-on-a-chip” 
model. Endothelial cells are cultured on mechanically tunable, enzymatically cross-linked gelatin 
and treated with deferoxamine, an iron chelator, or angiotensin II were used to simulate a nutrient 
deficient and diseased environment, respectively. As oxidative stress and disturbed barrier function 
are the most prevailing mechanism of angiotensin II and iron deficiency induced endothelial 
dysfunction, to test our model we investigated the changes in reactive oxygen species production 
and VE-cadherin expression in engineered endothelium. Both angiotensin II and deferoxamine 
treated engineered endothelium showed an increase in oxidative stress and disturbed barrier 
function. This in vitro model can be a useful tool to better understand disease mechanisms 
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1.1.1 Food insecurity 
Food insecurity is a growing concern in the United States. Food insecurity is a complex 
problem that impacts people of all communities and all age group. However, people in rural 
communities, African-Americans especially children, women, and seniors are mostly affected. 
According to USDA, 11.8% of American household in the US are food insecure where 7.3% of 
households have low food security and 4.5% of households have very low food security. In 
Mississippi, approximately, 17.2% of households are considered food insecure [1].  Cardiovascular 
diseases (CVDs) account for approximately 32% of total death in the world. According to 
American Heart Association, around 92.1 million US adults have at least 1 type of CVD and by 
2030, it is estimated that 43.9% of the US adult population will have some form of CVD [2]. 
1.1.2 Food insecurity and cardiovascular disease 
Studies suggest that poor diets that result from food insecurity can lead to a number of 
health effects including increased rates of iron-deficiency anemia, acute infection, and 
cardiovascular diseases. Food insecurity is also associated with clinical evidence of cardiovascular 
risk factors including hypertension [3]. Similarly, cardiometabolic risk factors including 
inflammation, endothelial health is influenced by dietary habits [4]. Clearly, maternal food 
insecurity leads to the birth of babies with low birth weight without catch-up growth, who will in 
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the long term also have an increased risk of cardiovascular diseases [5]. It is well known that the 
dietary trace elements containing nutrient supplies like copper, magnesium, iron are highly 
associated with cardiovascular disease [6]. Various data are available that suggest minimal effects 
of saturated fat and dietary cholesterol and stronger effects of other compounds such as iron, 
sodium on cardiovascular effects [7], [8].  Iron deficiency and iron deficiency anemia is the most 
prevalent nutritional deficiencies in the United States and worldwide. Therefore, food insecure 
people are significantly more likely to have iron-deficiency anemia than food secure people 
especially children and women; food insecure children are 2.4 times more likely to have iron 
deficiency anemia [9], [10]. Despite several studies associating food insecurity, nutritional 
elements, and cardiovascular disease, cardiovascular disease due to undernutrition is not fully 
understood. 
1.2 Background 
1.2.1 Cardiovascular risk factors and endothelial dysfunction 
The vascular endothelium is the main point of contact between vessels and blood  [11]. 
The functional integrity of the endothelium is an essential part of vascular homeostasis [12]. 
Among the various endothelial-derived factors, nitric oxide (NO) plays a crucial role in 
maintaining vascular homeostasis [13]. Reactive oxygen species (ROS) play a major role in NO-
based cell signaling. Oxidative stress affects NO availability in cells and leads to endothelial 
dysfunction which triggers vascular disorders [12]. Moreover, much evidence has been reported 
where the amount and duration of cardiovascular risk factor in the patient were independently 
predicted by the progression of endothelial dysfunction in addition to traditional risk factors [14]. 
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1.2.2 Role of oxidative stress and VE-cadherin in endothelial dysfunction 
The progression of endothelial dysfunction is a complex process and is influenced by 
factors such as oxidative stress and endothelial barrier integrity. Increased oxidative stress weakens 
the defense mechanism of the vascular endothelium, leading to endothelial dysfunction [15]. Up-
regulation of reactive oxygen species (ROS) can lead to the activation of nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase, NO inactivation, endothelin expression, and 
uncoupling of eNOS. During endothelial dysfunction, eNOS acts as a potential ROS generator 
[16]. Oxidative stress may increase vascular inflammation signaling pathways which increase the 
superoxide production by inflammatory cells leading to endothelial dysfunction [17]. 
The endothelium acts as a barrier between surrounding tissue and vessel lumen controlling 
the passage of blood proteins and cells into the vessel wall. Alteration in junction organization of 
endothelial cells changes the endothelial reaction with blood proteins and compromise endothelial 
hemostasis. Vascular Endothelial-cadherin (VE-cadherin), a specific adhesion molecule, located 
at the junction between the cells is found to have a crucial role in maintaining the barrier function 
of the endothelium [18]. VE-cadherin is also considered as a major factor in assessing vascular 
endothelial integrity and permeability. 
1.2.3 Role of Angiotensin II (ANG II) 
Angiotensin II (ANG II) is a peptide hormone of the renin-angiotensin system. The 
physiological effects of ANG II are mediated by angiotensin type 1 receptors (AT1Rs), and 
angiotensin type 2 receptors (AT2Rs) [19].  While ANG II mediates physiological vascular tone 
cascades and blood pressure regulation, it is also associated with pathological mechanisms such as 
inflammation, hypertrophy, and endothelial dysfunction. ANG II is considered a potent mediator 
of oxidative stress [20], [21]. Many ANG II-mediated effects which are implicated in the 
 
4 
pathogenesis of endothelial dysfunction are dependent on ROS [22]–[24].  ANG II up-regulates 
membrane NAD(P)H oxidases which leads to the generation of ROS, such as superoxide (O2
–) and 
hydrogen peroxide (H2O2)  [25]–[27]. ANG II-mediated generation of superoxide decreases the 
availability of nitric oxide (NO) in endothelial cells causing endothelial dysfunction [28]–[30]. 
ANG II  can disrupt cell junctions; thus, reducing endothelium integrity [31]. ANG II-treated mice 
heart tissue cleaved VE-cadherin demonstrating disruption in endothelial barrier [32]. VE-cadherin 
expression is decreased by ANG II in endothelial cells  [33]. Studies suggest that this mechanism 
is modulated by transforming growth factor (TGF-β1) [34], [35]. TGF- β1 induced disassembly of 
both adherence and tight junctional complexes and redistribution of cell cytoskeleton in human 
renal proximal tubular epithelial cells lead to loss of cell-cell contact [36]. 
1.2.4 Role of deferoxamine (DFO) 
Iron deficiency is the most common nutritional deficiency worldwide and is also 
associated with endothelial dysfunction [37]. Deferoxamine (DFO) is a well-known iron 
chelating agent and has been used in several studies to induce iron deficiency or to reduce iron 
overload [38], [39]. Tajima et al. demonstrated reduced fat iron concentration and serum ferritin 
levels in DFO treated mice compared to vehicle treated mice [40]. Increase in oxidative stress 
has been associated with iron deficiency. Knutson et al. reported that severely iron-deficient 
anemic rats showed a marked increase in lipid peroxidation, suggesting that iron deficiency 
promotes oxidative stress [41]. Previous morphological and biochemical studies have shown that 
iron deficiency induced increased oxidative stress is associated with mitochondrial dysfunction 
[42]. Walter et al. reported iron deficiency in Sprague– Dawley rats increased oxidant levels in 
polymorphonuclear leukocytes (PMNs), and increased mitochondrial DNA (mtDNA) 
fragmentation [43]; damage to mtDNA correlates with the mitochondrial dysfunction and is 
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associated with an increase in ROS [44]. Iron deficiency also has a deleterious effect on vascular 
permeability [45]. 
1.2.5 Gelatin and microbial transglutaminase (mTG) crosslinked hydrogel as a culture 
substrate 
Traditional in vitro systems do not recapitulate extracellular microenvironment [46]. 
Similarly, due to species-dependent differences, experiments with animal cells and animal models 
may not be always relevant to humans, which indicates the importance of developing an in vitro 
model with human-derived cells [47]. The extracellular matrix serves as a mechanical support for 
cells and plays a major role in cellular behavior and expression.  
Gelatin is a derivative of collagen, the primary extracellular matrix protein in native heart 
and endothelium. Therefore, it shows innate structural similarities to the extracellular matrix 
presenting extensive support for cellular adhesion and proliferation [48]. Gelatin hydrogels are 
typically not thermostable and form low viscosity solution at physiological temperatures, but it 
can be chemically crosslinked with enzymes such as microbial transglutaminase (mTG) to convert 
it into a thermostable hydrogel. Crosslinking with mTG ensures structural integrity with controlled 
and reproducible gel properties [49]. The gelatin-mTG cross-linked hydrogels have tunable elastic 
moduli which can be helpful to mimic elastic modulus of heart, improving their robustness and 
matching native mechanical microenvironment for extended cell culture of engineered cardiac 
tissue [50]. Due to the greater supply of matrix protein provided by the gelatin substrate, as cells 
remodel and degrade matrix protein on the surface of the substrate, additional cell adhesion sites 
throughout the bulk of the gelatin hydrogel become available. Therefore, cardiac tissues remained 
more viable and contractile in gelatin micro-molded chips over fibronectin microprinted soft 
PDMS substrates or traditional culture substrates [50]. 
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Similarly, mTG, a purified natural enzyme, has been used in numerous researches to 
crosslink gelatin and other cell adhesive molecules in order to create more biocompatible, tissue 
scaffolding or adhesives. In vivo, transglutaminase is present in several forms in ECM, blood, and 
on cell surfaces.  They are also expressed in many tissues and have functions in processes such as 
cell adhesion and migration, posttranslational modification of proteins, extracellular matrix 
remodeling and fibrin polymerization. In addition, the proteins in the mTG have transamidating 
activity and catalyze the formation of N-e-(c-glutamyl)lysine protein crosslinks [51]. Chau et al. 
reported transglutaminase treated collagen scaffold enhanced cell attachment and proliferation. It 
also showed reduced cytotoxicity, increased resistance of scaffold degradation and was resistant 
to proteolysis [52]. The advantages of using mTG for crosslinked hydrogels clearly indicate their 
superiority over other conventional crosslinkers ensuring low cytotoxicity and high 
biocompatibility. 
Studies have shown that cells perceive and respond to the rigidity of culture substrate. The 
substrate stiffness influence cell health and behavior [53]–[55]. Yeung et.al studied the effect of 
substrate stiffness on aorta endothelial cells and demonstrated abrupt changes in shape, 
cytoskeleton assembly and cell spreading when cultured on surfaces with stiffness ranging from 2 
to 55,000 Pa [56]. The extracellular substrate stiffness regulates endothelial cell stiffness via 
changes in actin cytoskeleton [57]. The mechanical stiffness of the substrate modulates endothelial 
cells capillary morphogenesis in vitro [58]. A significant difference in morphology was observed 
in cells grown on rigid tissue culture plastic regardless of the presence of ECM proteins as a coating 
than those grown on the flexible crosslinked gelatin substrates [51]. Similar observations were 
made when human cardiac microvascular endothelial cells were cultured on gelatin-mTG 
crosslinked hydrogel substrate. The cells on gelatin mTG hydrogel substrate showed more 
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elongated cell shape than cells cultured on a regular culture dish (Figure 1.0). This observation 
complements with the previous study, where endothelial cells grown on softer hydrogel substrate 
(25 kPa) showed more elongation in shape, whereas those grown on more stiff hydrogel surface 
(75 kPa) showed more like rounded shape [59]. Substrate stiffness also influences cell adhesion 
and proliferation [59]. These studies clearly demonstrate the importance of incorporating a softer 
and flexible culture substrate for in vitro experiments. Similarly, in traditional cultures conditions, 
ECM components are typically either absent or present only as a thin layer of protein adsorbed 
onto a rigid surface. Moreover, the elastic modulus of healthy human heart ranges from 10-20 kPa 
approximately [60]. Altering the concentrations of gelatin and mTG will help us to tune the 
elasticity of culture substrate and recapitulate mechanical properties of native endothelium which 
is impossible to do with traditional culture plates even coated with ECM. The rigid culture 
substrates even coated with ECM components do not mimic the mechanical aspects of the in vivo 
microenvironment. Therefore, the traditional in vitro culture condition is unable to correlate results 
to in vivo because of the significant differences between the in vitro and in vivo 
microenvironments. The gelatin-mTG crosslinked hydrogel based culture substrate may not only 
provide a more in vivo-like-in vitro culture environment but will also allow for a wider range of 
readouts that potentially are more physiologically relevant. This platform will also improve the 
accessibility of in vivo responses of cells to stimuli and could potentially allow for new types of 





Figure 1.1 A Confluent monolayer of human cardiac microvascular endothelial cells on 
different culture substrate. 
(A) Human cardiac microvascular endothelial cells cultured on a plastic culture substrate. (B). 
Human cardiac microvascular endothelial cells cultured on a gelatin hydrogel substrate (Scale 




DEVELOPMENT OF THE “NUTRIENT DEFICIENCY-ON-A-CHIP” MODEL 
2.1 Methods 
2.1.1 Materials required 
Human cardiac microvascular endothelial cells, Supplement Pack Endothelial Cell GM  
MV2, Endothelial Basal Medium MV2, Phosphate Buffered Saline (PBS), 0.25% Trypsin-EDTA 
1X, Dimethyl sulfoxide, Gelatin, Microbial Transglutaminase (mTG), 184 Silicone Elastomer kit, 
Bovine serum albumin (BSA), CellRox Green Reagent, anti-VE-cadherin, Triton X-100, 
Paraformaldehyde, Alexa FluroTM 546 goat anti-rabbit IgG (H+L), DAPI, Prolong Gold, (3-
Aminopropyl)trimethoxy-silane (ATPES), Glutaraldehyde, Ethanol, Angiotensin II (ANG II), 
Deferoxamine (mesylate) (DFO). 
2.1.2 Elastic modulus measurement 
2.1.2.1 Atomic force microscopy 
The elastic modulus of gelatin-mTG crosslinked chips for different concentrations of 
gelatin and mTG: 10% gelatin 1% mTG, 10% gelatin 0.8% mTG, 7% gelatin 1% mTG, 7% gelatin 
0.8% mTG was measured using Catalyst Atomic Force Microscopy (ZEISS) and conical silicon 
tip on nitride lever (model: SNL-10 (Veeco); B-fo = 14-26 KHz). Different concentration of gelatin 
and mTG solution was mixed together to get the desired concentration and measurement was done. 
In order to study the changes in elastic modulus of gelatin in culture condition measurement was 
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also done 24 hours after keeping prepared chips in culture condition. Measurement and analysis 
were done using Nanoscope 8.15 and Nanoscope Analysis 1.5 software. 
2.1.2.2 Mach-1 micromechanical system 
The elastic modulus of gelatin-mTG crosslinked hydrogels prepared from two different 
approaches was measured using the Mach-1 micromechanical system (Biomomentum). The first 
approach was crosslinking gelatin and mTG solution together to form hydrogel and second was 
crosslinking pre-cured pure gelatin hydrogel in mTG solution. Mach-1 motion (Model V500c, 
version 4.3.1.9) software and Mach-1 analysis (version 4.10.17) software were used. Compression 
test was done to obtain stress and strain values. Young’s modulus was calculated using the formula 
from Hooke’s Law: 
 E = stress / strain (2.1) 
 E = stress / strain (2.2) 
 E= (Fn / A) / (dl / lo) (2.3) 
Where, 
E = Young’s modulus (N/m2) 
ε = strain 
σ = normal stress 
Fn = normal force acting perpendicular to the area  
A = area  
dl = change of length 
lo = initial length 
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2.1.2.2.1 Crosslinking gelatin and mTG solution together to form a hydrogel 
Briefly, 3% agar solution was cured in a petri dish at room temperature and molds were 
created using a biopsy punch of diameter 8mm. Gelatin and mTG solutions were mixed together 
to form 7% gelatin 1% mTG mixture and 10% gelatin 1% mTG mixture. The prepared gelatin-
mTG solution was introduced to agar molds and cured at room temperature for an hour. After 1 
hour, agar was carefully removed to obtain gelatin-mTG crosslinked hydrogel. Prepared gelatin-
mTG crosslinked hydrogel cylinders were exposed to UV light for an hour and elastic modulus 
was measured. Additionally, prepared hydrogel cylinders were incubated in PBS at 37oC and 
elastic modulus was measured after 24 hours and 48 hours of incubation. 
2.1.2.2.2 Crosslinking pre-cured pure gelatin hydrogel in mTG solution 
Agar molds (3%) were prepared as discussed earlier. Sterile gelatin solutions (5% and 7%) 
were prepared, introduced into the agar molds, and cured at 4oC overnight. The gelatin hydrogel 
cylinders were carefully removed from agar mold. Gelatin cylinders were exposed to UV light for 
an hour and incubated in sterile 1% mTG solution at room temperature for 2 hours. After 2 hours, 
the mTG solution was aspirated and gelatin-mTG crosslinked hydrogel cylinders were rinsed with 
PBS. Thus, prepared gelatin-mTG crosslinked hydrogel cylinders were incubated in PBS at 37oC 
with continuous swirling using a rocking machine. PBS was changed twice in 24 hours and elastic 




2.1.3  Gelatin chip fabrication Process 
 
Figure 2.1 Fabrication procedure of crosslinked gelatin hydrogel chip. 
Glass coverslips (blue) were masked with low-adhesive tape (orange), laser-engraved to expose 
the center region of glass coverslips, and chemically activated to facilitate gelatin adhesion. 7% 
gelatin solution (yellow) was introduced on the coverslip and added PDMS stamp (purple) on top 
of gelatin. After overnight incubation at 4℃, the stamp and tape were removed. The construct 
was then incubated in 1% mTG solution (gray) for 2 hours, rinsed with PBS, incubated in PBS 
for 48 hours at 37oC and finally seeded with cells. 
Glass coverslips (10mmx10mm) were masked using low-adhesive tape and a laser 
engraver. Then, the coverslips were chemically activated to facilitate gelatin adhesion. Coverslips 
were treated with a mixture of Millipore water and 1M NaOH at a 9:1, the ratio for 5 minutes. 
Again, coverslips were treated with a mixture of 95% ethanol and APTES at a 100:0.5, the ratio 
for 5 minutes. Coverslips were rinsed with 95% ethanol for 5 minutes three times. After three 
ethanol rinses, coverslips were treated with a mixture of Millipore water and 70% glutaraldehyde 
at a 100:0.72 ratio for 30 minutes. Finally, coverslips were rinsed with Millipore water for 5 
minutes three times and dried at 65oC for 15-20 minutes. PDMS stamps were prepared using 184 
silicone elastomer kit at a 10:1, base: curing agent, ratio. The solution was then degassed and cured 
at 65oC overnight. The stamps were then cut into 10 mm x 10 mm blocks which were used to 
create a flat gelatin surface. 7% gelatin solution was prepared and dissolved at 55oC for 20 minutes. 
To ensure sterility, the gelatin solution was filtered using the 0.2µ filter. The sterile gelatin solution 
was introduced to an exposed portion of the coverslip and PDMS stamp was added on top of gelatin 
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solution. The stamped gelatin chip was cured at 4oC overnight. After curing, PDMS stamp and 
adhesive tape were carefully removed followed by UV sterilization for an hour. 1% mTG solution 
was dissolved at room temperature for an hour and was filtered using the 0.2µ filter. The pre-
formed gelatin hydrogel layer was crosslinked in mTG solution for 2 hours at room temperature. 
After 2 hours, the mTG solution was aspirated and the gelatin-mTG crosslinked chip was washed 
with PBS. Prepared gelatin chip was incubated in PBS at 37oC for 48 hours before seeding cells 
to stabilize elastic modulus of the gelatin layer. PBS was changed twice in 24 hours. 
2.1.4 Cell culture 
Human cardiac microvascular endothelial cells (HCMVEC) were purchased from Lonza 
and culture was done according to manufacturer’s instruction. Cells were cultured in complete 
EGM-2MV medium supplemented with 5% Fetal Calf Serum (FCS). Passages between 6 and 10 
were used for the experiments. 
2.1.5 Cell seeding and dosing 
HCMVEC were seeded on prepared gelatin-mTG crosslinked chips and dosed with ANG 
II and DFO in a time-dependent and dose-dependent manner. Cells were dosed with 5 nM, 100 
nM ANG II and 50 µM, 200 µM DFO, respectively. Cells were dosed 12 hours after seeding and 
subsequent doses were in every 24 hours. Drugs were diluted in growth medium supplemented 
with 5% FCS for dosing up to 24 hours and then with 0.25% BSA was added to growth media 
supplemented with 0% FCS. 
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2.1.6 Immunofluorescence study 
 
Figure 2.2 Angiotensin II and deferoxamine induced vascular permeability experimental 
protocol. 
 
Cells were seeded at 30,000 cells /mm2 and dosed with ANG II (0 nM, 5 nM, and 100 nM) 
and DFO (0 µM, 50 µM, and 200 µM). Samples were collected 24 hours and 1 week after dosing 
(Figure 2.2). Briefly, collected samples were fixed and permeabilized using 4% Paraformaldehyde 
and 0.05% Triton X-100 for 15 minutes. Samples were washed with PBS for 5 minutes 3 times. 
Cells were incubated with 1% Bovine serum albumin (BSA) to block nonspecific binding, stained 
with anti-VE-cadherin (primary) (1:200) overnight at 4oC and washed with PBS for 20 minutes 
three times. Again, cells were stained with secondary antibody Alexa Fluro 546 goat anti-rabbit 
IgG (H+L) (1:200) and DAPI (0.5:100) for an hour at room temperature and washed with PBS for 
20 minutes three times. Samples were mounted using Prolong Gold Anti-fade. Imaging was done 
in a fluorescence microscope and images were quantified using ImageJ software. The fluorescence 
intensity of the immunofluorescence stained images was determined using “integrated density” 
feature in ImageJ under “Analyze-Set Measurements” similar to earlier publications [61]. The 
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fluorescence intensity was determined using the formula “Corrected total cell fluorescence (CTCF) 
= Integrated Density - (Area of Section X Background fluorescence)” [62] and expressed in terms 
of arbitrary units. 
2.1.7 Oxidative stress assay 
 
Figure 2.3 Angiotensin II and deferoxamine induced oxidative stress experimental protocol. 
 
Briefly, well-surface of 96-well plate was coated with Gelatin-mTG crosslinked layer 
following the same procedure for preparing gelatin chips in glass coverslips. Cells were seeded at 
50,000 cells per well. Cells were exposed to ANG II (0 nM, 5 nM, 100 nM, and 1 µM) and DFO 
(0 µM, 50 µM, and 200 µM) for 1 hour, 24 hours, 72 hours and 1 week (Figure 2.3). The kinetics 
of ANG II and DFO induced production of ROS in the engineered endothelium was assessed using 
the CellROX Green reagent. CellROX Green reagent is a ROS-sensitive dye and a DNA 
fluorogenic probe, therefore upon oxidation in an elevated ROS environment, CellROX Green 
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binds to DNA; thus, its green fluorescence signal is localized primarily in its nucleus and 
mitochondria [63]–[65]. Cells treated with drugs were treated with CellROX Green Reagent at a 
final concentration of 5 μM and incubated for 30 minutes at 37°C. After 30 minutes, cells were 
washed with PBS for 3 times and incubated with growth media. Fluorescence of the oxygenized 
reagent was measured using a Cytation5 plate reader and Gen 5 3.00 software at 37oC, 5% CO2. 
Signal was read every 10 minutes for 2 hours at an excitation and emission wavelength of 485 nm 
and 528 nm, respectively. Mean fluorescence intensity was used to represent each sample's ROS 
level. Background signal was determined by running a negative control sample and subtracted 
from measured signals. Each condition was tested in triplicate. 
2.1.8 Statistical analysis 
Each experiment is done in three independent experiments (n=3). Data are represented as 
mean ± standard deviation. For multiple mean comparisons, ANOVA followed by Tukey test was 
performed with Microsoft Excel. P-values less than 0.05 or 0.01 were considered statistically 
significant and are also indicated appropriately. 
2.2 Results 
2.2.1 Elastic Modulus of gelatin-mTG crosslinked chip 
The thermal instability of gelatin requires the use of a crosslinker like mTG to stabilize the 
hydrogel at physiological temperatures. The previous studies have suggested, the elastic modulus 
of gelatin and mTG crosslinked hydrogel increases with the increase in concentration and 
crosslinking time of gelatin and mTG. Studies show that the cell culture substrate stiffness can 
influence cellular behavior [55], [66]. Therefore, one of the goals was to create a stable elastic 
modulus for the culture substrate.  We examined 7% and 10% gelatin formulations with atomic 
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force microscopy (AFM). The mTG concentration (0.8% and 1%) was also varied to determine 
the optimal concentration that would result in an acceptable modulus yet durable enough to 
withstand handling required for chip assembly. An equal volume of gelatin and mTG solutions 
were mixed together to get the desired concentration. All formulation tested resulted in gels that 
were within the range 10-20 kPa (Figure 2.4A). We found that the modulus of gelatin-mTG 
crosslinked hydrogel increased with time suggesting a potential dynamic stiffening within the gels. 
Therefore, our next question was would the elastic modulus of crosslinked gelatin be stable when 
kept in culture condition. We incubated the prepared chips in culture condition (in PBS at 37oC 
5% CO2) for 24 hours and measured changes in elastic modulus. We observed the elastic modulus 
of 10% gelatin 1% mTG significantly increased from 20.60 ± 3.29 kPa to 76.72 ± 20.34 kPa 
(Figure 2.4A, 2.4B) in 24 hours. Similarly, the elastic modulus of 7% gelatin 1% mTG 
significantly increased from 13.92 ± 1.88 kPa to 38.45 ± 5.35 kPa (Figure 2.4A, 2.4B) in 24 hours. 
Therefore, the elastic modulus of gelatin-mTG crosslinked hydrogel significantly increased with 
increase in concentration and time (Figure 2.4A, 2.4B). We conducted a similar study using Mach-
1 to compare the results from AFM and observed similar results. Both 7% gelatin 1% mTG (Figure 
2.5A) and 10% gelatin 1% mTG (Figure 2.5B) showed a significant increase in elastic modulus in 




Figure 2.4 The elastic modulus for different concentrations of gelatin and microbial 
transglutaminase measured with atomic force microscopy. 
(A) Displays elastic modulus for different concentrations of gelatin and mTG after 2 hours of 
crosslinking. (B) Displays elastic modulus for different concentrations of gelatin and mTG 
crosslinked hydrogel after incubating for 24 hours in culture condition (in PBS at 37°C, 
5% CO2, and a humidified atmosphere) (n = 3, Mean ± Standard deviation, * indicates P-





Figure 2.5 The elastic modulus for different concentrations of gelatin-microbial 
transglutaminase crosslinked hydrogel measured with Mach-1. 
Gelatin and mTG solutions were mixed together to get the desired concentration. (A) Displays 
elastic modulus for 7% gelatin and 1% microbial transglutaminase. (B) Displays elastic modulus 
for 10% gelatin and 1% microbial transglutaminase. Crosslinked hydrogels were incubated in 
culture condition (in PBS at 37°C, 5% CO2, and a humidified atmosphere) for 24 hours and 48 
hours without a rocker. (n=3, Mean ± Standard deviation, * indicates P-value < 0.01) 
 
Previous results of elastic modulus obtained from Mach-1 showed a significant increase in 
elastic modulus of gelatin and mTG crosslinked hydrogel when kept in a culture condition. 
Therefore, we tried another approach of chip fabrication where pre-cured gelatin hydrogel was 
incubated in mTG solution and then was swirled continuously in PBS. We measured temporal 
changes in elastic modulus over 72 hours to determine the time needed for crosslinking 
stabilization. There was no significant increase in elastic modulus for both 5% gelatin hydrogel 
crosslinked in 1% mTG solution (Figure 2.6A) and 7% gelatin hydrogel crosslinked in 1% mTG 
solution (Figure 2.6B) when incubated in culture condition for 72 hours using a rocker. Although, 
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the elastic modulus of 5% gelatin hydrogel crosslinked in 1% mTG solution was more stable and 
closely matched the elastic modulus of native heart (10-20 kPa) in comparison to 7% gelatin 
hydrogel crosslinked in 1% mTG solution, the gels often fractured during later fabrication steps 
and handling, limiting their utility as a robust experimental platform. Thus, for further study, we 
chose to continue with 7% gelatin hydrogel cross-linked in 1% mTG solution, which had an elastic 
modulus of approximately 17 kPa and better matched the elastic modulus of the native heart 
compared to traditional culture substrates. Moreover, the thickness of the gelatin layer on the 
prepared chip was dictated by the thickness of the adhesive tape which is approximately 100µm. 
Therefore, the thickness of gelatin hydrogel should be sufficiently thick to minimize the effects of 







Figure 2.6 The elastic modulus for different concentrations of pre-cured gelatin hydrogels 
crosslinked in microbial transglutaminase solution and measured on Mach-1. 
(A) 5% gelatin and (B) 7% gelatin solution were cured for overnight at 4oC in agar mold 
followed by UV sterilization for an hour. Pre-cured hydrogels were incubated in 1% microbial 
transglutaminase solution for 2 hours at room temperature. Crosslinked hydrogels were also 
incubated in culture condition (in PBS at 37°C, 5% CO2, and a humidified atmosphere) for 24 
hours and 48 hours and 72 hours with a rocker. (n=3, Mean ± Standard deviation). 
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2.2.2 Angiotensin II-induced oxidative stress 
 
Figure 2.7 Angiotensin II-induced oxidative stress. 
HCMVEC were treated with 0, 5 nM, 100 nM, and 1 µM ANG II for 1 hour, 24 hours, 72 hours 
and 1 week. ROS production was evaluated using CellROX Green reagent. (A) The graph 
represents ROS production at initial plate reading. (B) The graph represents ROS production at 1 
hour of plate reading. (C) The graph represents ROS production at 2 hours of plate reading. 
There was no significant difference in ROS production at 1 hour and 24 hours ANG II-treated 
cells, however, at 1 week and 72 hours ANG II-treated cells produced significantly higher ROS 
than control cells. (n=3, Mean ± Standard deviation, * indicates P-value < 0.01 relative to 
respective time point and # indicates P-value < 0.05 relative to respective time point). 
 
HCMVEC was treated with 0, 5 nM, 100 nM and 1 µM ANG II for 1 hour, 24 hours, 72 
hours and 1 week. The kinetics of ANG II-induced production of ROS in HCMVEC was studied 
for 2 hours in an interval of every 10 minutes. During the initial reading (Figure 2.7A), we observed 
that there was no significant difference in ROS production between control, 5 nM, 100 nM, and 1 
µM ANG II-treated cells for 1 hour and 24 hours.  The 72 hours and 1 week time-point 5 nM, 100 
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nM and 1 µM ANG II produced higher ROS than control. At 72 hours, 100 nM and 5 nM ANG II 
treatment produced significantly higher ROS than control and 1 µM ANG II treatment. At 1week, 
5 nM, 100 nM, and 1 µM produced significantly higher ROS than control. However, there was no 
significant difference among the ANG II-treated groups with 1 week of exposure.  
Similar results were observed in 1 hour and 2 hours of plate reading (Figure 2.7B, 2.7C). 
There was no significant change in ROS production in cells after 1 hour and 2 hours of reading. 
Similar to initial reading, at 1 hour and 2 hours of reading time point, there was no significant 
difference in ROS production between control, 5 nM, 100 nM, and 1 µM ANG II treatment for 1 
hour and 24 hours. Cells treated for 72 hours and 1 week showed significantly higher oxidative 
stress in 5 nM, 100 nM, and 1 µM than in control. The only difference observed was that during 
initial reading, 72 hours 5 nM ANG II treatment produced significantly higher ROS than 1 µM 
ANG II, however, during 1 hour and 2 hours reading we observed no significant difference in ROS 
production between 5 nM and 1 µM ANG II treatment for 72 hours.  
Similarly, during the kinetic study of ANG II-induced ROS production for 2 hours we did 
not observe any significant change in kinetic ROS production by control, 5 nM, 100 nM and 1 µM 
ANG II-treated for 1 hour, 24 hours, 72 hours and 1 week, however, at 72 hours 1 µM ANG II-
treated cells produced higher ROS throughout the 2 hours of kinetic experiment (Figure A.1). 
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2.2.3 Deferoxamine induced oxidative stress 
 
Figure 2.8 Deferoxamine induced oxidative stress. 
HCMVEC were treated with 0, 50 µM and 200 µM DFO for 1 hour, 24 hours, 72 hours and 1 
week. ROS production was evaluated using CellROX Green reagent. (A) The graph represents 
ROS production at initial plate reading. (B) The graph represents ROS production at 1 hour of 
plate reading. (C) The graph represents ROS production at 2 hours of plate reading. There was 
no significant difference in ROS production at 1 hour and 24 hours DFO treated cells, however, 
at 1 week and 72 hours a significant difference in ROS production was observed between DFO 
treated and control cells. (n=3, Mean ± Standard deviation, * indicates P-value < 0.01 relative to 
respective time point and # indicates P-value < 0.05 relative to respective time point) 
 
HCMVEC was treated with 0, 50 µM and 200 µM DFO for 1 hour, 24 hours, 72 hours and 
1week. The kinetics of DFO induced ROS production in HCMVEC was studied for 2 hours in an 
interval of every 10 minutes. The initial reading (Figure 2.8A) revealed that at 1 hour 50 µM DFO 
treated cells produced higher ROS than 200 µM DFO and control. At 24 hours there was no 
significant difference between control, 50 µM and 200 µM DFO treated cells. However, at 72 
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hours 200 µM DFO produced significantly higher ROS than 50 µM DFO and control cells. At 1 
week time point, 200 µM and 50 µM DFO produced higher oxidative stress than control. However, 
there was no significant difference among the DFO treated groups with 1week of exposure.  
Similar results were observed in 1 hour and 2 hours of reading (Figure 2.8B, 2.8C). Similar 
to initial reading, at 1 hour and 2 hours of reading time point, cells treated with 50 µM DFO for 1 
hour showed slightly higher oxidative stress than 200 µM and control.  There was no significant 
difference between control, 50 µM and 200 µM DFO treated cells for 24 hours. At 72 hours, 200 
µM DFO produced significantly higher oxidative stress than 50 µM DFO and control treated cells. 
At 1 week, 200 µM and 50 µM DFO produced significantly higher oxidative stress than control. 
During the initial reading, 1 week 50 µM DFO exposed and control cells did not show a significant 
difference in ROS production. However, at 1 hour and 2 hours plate reading 1week 50 µM DFO 
treatment produced significantly higher ROS than control (Figure 2.8). Similarly, there was no 
significant change in ROS production during the kinetic experiment for cells treated with 1 hour 
DFO.  Insignificant fluctuations in the kinetic ROS production were observed for 24 hours of DFO 
exposure. Cells treated with 50 µM DFO for 72 hours significantly increased ROS production and 
reached a peak at approximately 50 minutes and began to decrease after 50 minutes. Only 50 µM 
DFO treated for 24 hours and 72 hours showed a significant change in kinetic ROS production 
(Figure A.2). 
2.2.4 Effects of angiotensin II on barrier function 
The engineered endothelium were treated with 5 nM, and 100 nM of ANG II for 24 hours 
and 1 week and were stained with anti-VE-cadherin. ANGII-induced endothelial barrier 
dysfunction was studied and compared against untreated controls. A discontinuous and disrupted 
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VE-cadherin staining pattern was observed in cells treated with 5 nM and 100 nM ANG II for 1 
week (Figure 2.9). The fluorescence signal along the cell junctions of cells exposed to 5 nM and 
100 nM ANG II-for 1week was significantly low than untreated cells (Figure 2.9, 2.10). Further, 
the staining pattern and intensity did not change in cells treated with ANG II for 24 hours (Figure 
2.9, 2.10). 
 
Figure 2.9 Effect of angiotensin II on barrier function. 
Engineered endothelium were treated with ANG II (0, 5 nM, and 100 nM) for 24 hours and 1 
week.  Collected samples were stained with VE-cadherin to study barrier function. The 
fluorescence intensity and staining pattern remained the same for (A) Control 24 hours (B) 5 nM 
ANG II 24 hours (C) 100 nM ANG II 24 hours and (D) Control 1 week, however, reduced 
fluorescence intensity and disrupted staining pattern was observed on cells treated with (E) 50 





Figure 2.10 Effect of angiotensin II on VE-cadherin. 
Engineered endothelium were treated with ANG II (0, 5 nM, and 100 nM) for 24 hours and 1 
week.  Collected samples were stained with VE-cadherin to study barrier function. There was no 
significant difference between ANG II-treated and control cells at 24 hours, however, at 1 week 
significantly reduced fluorescence intensity was observed on cells treated with 5 nM and 100 nM 
ANG II. (n=3, Mean ± Standard deviation, * indicates P-value < 0.01 vs control of respective 
time point) 
2.2.5 Effects of deferoxamine on barrier function 
To investigate DFO induced endothelial barrier dysfunction, the engineered endothelium 
were treated with 0, 50 µM, and 200 µM DFO for 24 hours and 1 week. The treated engineered 
endothelium were stained with anti-VE-cadherin and were observed under a fluorescence 
microscope. A fragmented and discontinuous staining pattern was observed in cells treated with 
DFO for both 24 hours and 1 week (Figure 2.11). The fluorescence intensity of VE-cadherin was 
significantly lower than control after 24 hours or 1 week of treatment with 50 µM and 200 µM 




Figure 2.11 Effect of deferoxamine on barrier function. 
Engineered endothelium were treated with DFO (0 µM, 50 µM, and 200 µM) for 24 hours and 1 
week. Collected samples were stained with VE-cadherin to study barrier function. Reduced 
fluorescence intensity and a disrupted VE-cadherin pattern were observed on cells treated with 
50 µM and 200 µM DFO for 24 hours and 1 week (B, C, E, and F). (Scale bars: 100 µm, 





Figure 2.12 Effect of deferoxamine on VE-cadherin. 
Engineered endothelium were treated with DFO (0, 50 µM and 200 µM) for 24 hours and 1 
week.  Collected samples were stained with VE-cadherin to study barrier function. Significantly 
reduced fluorescence intensity was observed on cells treated with 50 µM and 200 µM DFO for 
24 hours and 1 week. (n=3, Mean ± Standard deviation, * indicates P-value < 0.01 vs control of 
respective time point) 
 
2.3 Discussion 
In this study, we created a gelatin-based in vitro system which is the preliminary stages of 
the “nutrient-deficiency on a chip” model. We first created an engineered endothelium by culturing 
HCMVEC on the crosslinked gelatin hydrogel chip, then we treated the engineered endothelium 
with DFO (0, 50 µM, and 200 µM) to induce iron deficiency. As previous studies suggest ANG II 
has been shown to induced endothelial dysfunction and also contributes to the pathophysiology of 
cardiovascular diseases, we also treated engineered endothelium with ANG II (0, 5 nM, 100 nM, 
and 1 µM). We tested our model by studying oxidative stress and the barrier function of the 
engineered endothelium.  
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ANG II is strongly incriminated in the pathogenesis of vascular injury and therefore is a 
growing body of evidence that ANG II induces oxidative stress in cells [26], [67]–[69].  In this 
study, we observed a significant rise in ROS production in cells treated with 5 nM, 100 nM, and 1 
µM ANG II for 72 hours and 1week was observed in comparison to control cells, which suggests 
that exposure to ANG II elevates the oxidative stress in cells. Our data complement that exposure 
of endothelial cells to ANG II induces oxidative stress in vitro and in vivo [67]. Generation of ROS 
by ANG II may contribute to progressive vascular injury through diverse mechanisms.  Oxidative 
stress in smooth muscle cells and endothelial cells may arise from stimulation of membrane-bound 
NADH/NADPH oxidase which increases the generation of superoxide anion [26], [69]. Besides 
endothelial cells, NADH/NADPH oxidase-induced oxidative effects of ANG II has also been 
found in smooth muscle cells, mesangial cells and LLC-PK1 cells in vitro [70], [71]. Also, 
administration of ANG II has been found to elevate several markers of oxidative injury such as 
lipid peroxidation, protein carboxyl content, hydroxyl radicals (OH) [67].  Besides, activation of 
NADPH/NADH oxidase system ANG II also exerts oxidation stress via stimulation of numbers of 
cytokines which are pro-oxidants [72], [113]. 
Iron is an important trace element for fundamental metabolic processes in living cells. 
Both, iron overload and iron deficiency are associated with the production of ROS that includes 
superoxide radical anion, hydrogen peroxide, and the hydroxyl radical [73]. In this study, we 
observed a significant rise in ROS production in cells treated with DFO for 72 hours and 1week in 
comparison to control cells. The results suggested that DFO induced iron deficiency elevated the 
oxidative stress in cells. Also, exposure to 50 µM DFO for 24 hours and 72 hours showed a 
significant change in kinetic ROS production. Iron deficiency derived oxygen stress can cause 
organ dysfunction via damage to DNA, lipids, and proteins [74]. Jagadeesen et al. studied lipid 
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peroxidation and activities of different antioxidant enzymes in iron deficiency and found iron-
deficient rats showed an elevation in lipid peroxidation and were more susceptible to oxidative 
stress. The increase of superoxide radical is fostered by iron inadequacy, leading to persistence of 
O2 radicals which give rise to other ROS such as OH [75]. Walter et al. reported iron-deficient rats 
developed free radical mitochondrial DNA (mtDNA) damage [43]. Impaired mtDNA induces an 
increase in ROS production [76]. Latif et al. reported that iron-starved cells demonstrated a 10-
fold increase of ROS levels and increased lipid peroxidation compared to cells grown with normal 
iron [77].  
Oxidants create cytotoxicity to cells in the vascular system. Oxidants also induce activation 
of endothelial cells. ROS upregulates pro-inflammatory and chemotactic substances, and also 
promotes inflammatory responses [78], [79], [112]. Additionally, there is mounting evidence that 
oxidative stress induces factors which up-regulates pro-inflammatory species like transcription 
factor, namely, nuclear factor-kβ (NF- kβ); pro-inflammatory and chemotactic substances 
adhesion molecules, selectin (E-selectin and P-selectin), T-cell chemoattractants (RANTES), and 
the monocyte-chemo attractants (MCP-1) [78], [79], [112]. Previous studies suggest that ANG II 
promotes these factors [72], [80]–[82]. Therefore, the elevation of ROS by ANG II and DFO in 
engineered endothelium contributes to the progression of factors that causes endothelial 
dysfunction and vascular injury. 
Similarly, we observed no significant difference in VE-cadherin intensity in cells treated 
with ANG II for 24 hours, however, a fragmented pattern and lower fluorescence signal of VE-
cadherin was observed in 1week ANG II treatment. Our results regarding the endothelial barrier 
function are consistent with several published observations. Yoshioka et al. also demonstrated 
ANG II treatment caused disruption of VE-cadherin in endothelial cell junctions resulting in 
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defective junction assembly  [83]. Pupilli et al. evaluated the role of ANG II in regulating vascular 
endothelial growth factor (VEGF)- a prominent regulator for vascular permeability in human 
mesangial cells in vitro and found that both mRNA and secretion of VEGF was significantly higher 
in cells treated with 10 nM, 100 nM, and 1 µM ANG II than control [84]. Similarly, Sano et al. 
studied the relationship between ANG II, VEGF and vascular permeability in human 
microvascular endothelial cells. VEGF induced disruption of VE-cadherin was suppressed by 
ANG II type 1 receptor (AT1R) blocker in vitro.  AT1R-deficient mice also inhibited 
hyperpermeability and VEGF-induced gap formation between endothelial cells [85]. We also 
observed that DFO treatment induced discontinuous and fragmented VE-cadherin with lower 
intensity in 24 hours and 1 week. Beerepoot et al. found that iron deficiency induced by several 
iron chelators including DFO up-regulated vascular endothelial growth factor (VEGF), which is a 
most potent vascular permeability factor [38]. VEGF treatment causes disruption in intercellular 
junctions of capillaries and small venules within minutes of treatment [86]. Several other studies 
describe the mechanisms of VEGF induced vascular permeability [87]–[89]. These findings 
strongly suggest ANG II and iron deficiency affects endothelial barrier function. The observed 
result of ANG II or DFO induced decrease of adherens junction protein VE-cadherin is due to the 
association of ANG II or iron deficiency on cell junction. Previous studies suggest oxidative stress 
is directly responsible for endothelial cell leakiness [90], [91]. Therefore, the ANG II and DFO 
induced disruption in VE-cadherin may be promoted by ANG II and DFO induced oxidative stress. 
ROS produced by endothelial cells at reoxygenation increases the formation of gap structures 
between endothelial cells via changes in actin cytoskeletal dynamics. P. L. Apopa et al. 
demonstrated that elevation of intracellular ROS causes disruption of VE-cadherin and increases 
permeability in a confluent monolayer of human microvascular endothelial cells through 
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cytoskeletal damage [91]. T. N. Meyer et al. developed a model in which oxidative stress 
compromises cell junction. Exposure to hydrogen peroxide for 30 minutes or 60 minutes 
significantly decreased transendothelial resistance and observed disruption in junction proteins 
cadherin, ZO-1, occludin during immunofluorescence study [92]. Previous studies also suggest 
that exposure of endothelial cell monolayers to ROS generators like glucose/glucose oxidase or 
xanthine/xanthine oxidase increases endothelial cell permeability in a dose-dependent manner 
through oxidative stress [93], [113].  
Several studies suggest the role of ANG II in the redistribution of the cytoskeletal system 
[94]–[96]. Similarly, iron is critical for normal functioning of the signaling cascade that regulates 
cytoskeletal dynamics [97]–[99]. Numerous studies also refer to coordination between cytoskeletal 
system, endothelial cell adhesion and barrier function. The cadherins and cytoskeletal system bind 
via catenins (α-, β-, and γ-catenins). Therefore, remodeling of the cytoskeletal system affects the 
regulation of cadherins [100], [101]. Therefore, ANG II and DFO induced inhibition of VE-
cadherin may be due to ANG II and DFO-induced oxidative stress itself and cytoskeletal 
remodeling induced by ANG II and DFO. 
We assert that the developed model of which is a preliminary step towards nutrient-deficiency-on-
a-chip can serve as a suitable platform for investigating nutrient deficiency disease mechanism and 
pharmaceutical applications. In this study, we created a DFO induced nutrient deficient 
endothelium model and ANG II-induced endothelial dysfunction model. The DFO induced iron 
deficient model mimics features of endothelium dysfunction and offers an ability to independently 
study the nutrient deficient effects on the function of the endothelium. The present study highlights 
engineered endothelium that are cultured in the static condition, however, the vascular 
endothelium is in intimate contact with blood and is directly exposed to various fluid mechanical 
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forces generated by pulsatile blood flow. The hemodynamic force has a crucial role in regulating 
endothelial structure and function [102]. The functional phenotype of vascular endothelium is 
dynamically responsive to the biomechanical stimuli generated by pulsatile flow of blood. The in 
vitro flow systems help to investigate the fluid shear stress stimulated cell biological effects in 
cultured monolayer of endothelium. The in vitro flow studies are able to recapitulate the features 
of endothelial cells that are similar to endothelial cells in vivo [103]. Vascular endothelial cells 
change cell shape from polygonal to ellipsoidal and become uniformly oriented with the flow when 
subjected to time and force dependent fluid shear stress [114]. Blood flow induced wall shear stress 
also lead to dynamic changes in intracellular Ca2+ concentrations which is essential for generation 
of ROS and activation of signaling pathways that result in disassembly of VE-cadherin and trigger 
endothelial permeability [104]–[106]. It has also been suggested that changes in shear stress cause 
reorganization of junction-associated proteins which affect permeability in endothelial cells [107]. 
Endothelial cells cultured under static conditions show low bio-ability of NO production, as well 
as the synthesis of eNOS mRNA and protein in comparison to cell subjected to shear stress [108], 
[109]. Developing a gelatin hydrogel based microfluidic device with similar gelatin culture 
substrate fabricating technology in future can be useful to overcome the limitation of this study 






2.4 Conclusions and future work 
2.4.1 Conclusions 
In the present study, we probed to recapitulate DFO induced nutrient deficiency model 
using an engineered endothelium. We demonstrated that ANG II and DFO-induced iron deficiency 
increases the oxidative stress in a dose-dependent and time-dependent manner. ANG II and DFO 
induced iron deficiency also disrupts the barrier function in HCMVEC and increases vascular 
permeability. Increased oxidative stress and disturbed barrier function contribute to endothelial 
dysfunction triggering cardiovascular events. The developed model can be further utilized to 
investigate genetic, morphological, and functional changes due to iron deficient diet on the model 
endothelium. This biomimetic nutrient deficient endothelium platform can be beneficial to 
investigate the underlying mechanisms of endothelial dysfunction in cardiovascular disease. 
2.4.2 Future work 
Gelatin-based microfluidic technologies are emerging as a promising tool for various 
applications in tissue engineering and cell biology, such as co-culture, microvasculature, and tissue 
assembly [51] [110]. In this study, we highlighted the nutrient deficient model which consists of 
endothelial cells however, the cardiovascular system consists of cells such as smooth muscle cells, 
fibroblasts. Therefore, a co-culture system can be developed in the future using a similar chip 
fabrication technique to understand the relation between nutrient deficiency and CVD. The 
fabrication technique developed in this research can also be helpful to develop a gelatin hydrogel 
based biomimetic vasculature chip containing simplified branching geometries that mimic the 
mechanical and structural properties of the native vasculature. Similarly, in this study, we probed 
oxidative stress and endothelial barrier function on the DFO induced nutrient deficient model and 
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ANG II-induced endothelial dysfunction model.  However, endothelial dysfunction includes 
several other markers such as nitric oxide generation, adhesion molecules, chemokines [111], 
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Figure A.1 Angiotensin II induced kinetic ROS production. 
The kinetic study was done for 2 hours in every 10 minutes. (A) The graph represents the kinetic 
reactive oxygen species production by HCMVEC treated with 0, 5 nM, 100 nM, 1 µM ANG II 
for 1 hour. (B) The graph represents the kinetic reactive oxygen species production by 
HCMVEC treated with 0, 5 nM, 100 nM, 1 µM ANG II for 24 hours. (C) The graph represents 
the kinetic reactive oxygen species production by HCMVEC treated with 0, 5 nM, 100 nM, 1 
µM ANG II for 72 hours. (D) The graph represents the kinetic reactive oxygen species 





Figure A.2 Deferoxamine induced kinetic ROS production. 
The kinetic study was done for 2 hours in every 10 minutes. (A) The graph represents the kinetic 
reactive oxygen species production by HCMVEC treated with 0, 50 µM, 200 µM DFO for 1 
hour. (B) The graph represents the kinetic reactive oxygen species production by HCMVEC 
treated with 0, 50 µM, 200 µM DFO for 24 hours. (C) The graph represents the kinetic reactive 
oxygen species production by HCMVEC treated with 0, 50 µM, 200 µM DFO for 72 hours. (D) 
The graph represents the kinetic reactive oxygen species production by HCMVEC treated with 0, 
50 µM, 200 µM DFO for 1 week. (n=3, Mean ± Standard deviation, * indicates P-value < 0.01 
relative to 0 minute and # indicates P-value < 0.05 relative to 0 minute) 
 
